Precision Cardiology Market Analysis

Precision Cardiology Industry Insights

Offering Analysis

As of 2024, the precision cardiology market is dominated by the service category with a market share of around 70%. This bifurcation is also expected to witness the higher CAGR in the market, of 10.3%, during the forecast period.

This is primarily attributed to the rising emphasis on the adoption of precision medicine in clinical settings. Moreover, underlying factors, such as sedentary lifestyle, unhealthy diet, obesity, and the growing population of pre-diabetics and diabetics worldwide, are imposing a combinatorial effect upon the global burden of CVDs, which results in the rising precision diagnosis’ services demand.

The following offerings are covered in the report:

• Service (Larger and Faster-Growing Category)
• Product

Sample Analysis

The blood category dominates the market with 65% share in 2024. This is because blood is widely extracted from the body for routine disease analysis. Further, blood analysis allows for the swift discovery of precise biomarkers for assessing the severity of diseases, as well as determining the effectiveness of therapy. In addition, there are well-established protocols and methodologies for extracting, handling, processing, and analyzing blood, and the years of experience in hematology has made the process simpler and cost-effective.

The non-blood samples category is predicted to grow at the higher CAGR in the market during 2024–2030. This can be primarily due to the clinical utilities of non-blood samples, which have been well-established and documented for conducting precision tests. Moreover, the companies operating in the market are actively involved in developing advanced tests based on non-blood-based samples, such as saliva and buccal swab specimens, which, in turn, boost the sales of these samples.

The report offers analysis for the following samples:

• Blood (Larger Category)
• Non-Blood (Faster-Growing Category)
  • Saliva
  • Buccal swabs
  • Others

Technology Analysis

The sequencing category accounts for the highest revenue, in 2024. The category is also expected to witness the fastest growth in the coming years. This is due to its clinical advantages, including higher accuracy, low cost of sequencing, broader coverage, and high scalability. In particular, NGS provides large sets of critical data on DNA and genes, aided by technological advancements in analyzers and software. Moreover, this technique can be utilized to sequence the entire genome or exome, as well as to run genetic panels. To make it better, it is being integrated with ML, AI, and other advanced technologies, which is further expanding its scope of application.

We have analyzed the below-mentioned technologies:

• Sequencing (Largest and Fastest-Growing Category)
  • Next-generation sequencing (NGS)
  • Sanger sequencing
• Polymerase Chain Reaction (PCR)
• Microarray
• Others

Application Analysis

The cardiomyopathy application accounts for the largest share, of 45%, in 2024. This is attributed to the increasing global incidence of various types of cardiomyopathies, the rising focus on research for the development of novel molecular diagnostic solutions, and the surging adoption of precision medicines, among others. For instance, according to the American College of Cardiology, the global prevalence of alcoholic cardiomyopathy is over 700,000 cases.

The arrhythmia category will like grow the fastest over the forecast period. This is attributed to the increasing prevalence of abnormal heart rhythms, which can often be fatal if not treated in time. For instance, over 2.5 million people in the U.S. have atrial fibrillation, which can cause heart failure or stroke, if persistent and not addressed immediately. Ventricular fibrillation is another serious arrhythmia, and it is a common cause of sudden cardiac death. Arrhythmias can be difficult to predict as they have a variety of causes, from underlying heart conditions and genetic predisposition to obesity and electrolyte imbalance.

The following are the categories in the application segment:

• Cardiomyopathy (Largest Category)
• Arrhythmia (Fastest-Growing Category)
• Aortopathy and Vascular Diseases
• Familial Hypercholesterolemia (FH)
• Congenital Heart Defects and Syndromes
• Others

End User Analysis

Hospitals and diagnostic laboratories are the primary end users, with a share of 55%, in 2024. They are also predicted to witness the highest CAGR, of 10.5%, during the forecast period. Hospitals and diagnostic laboratories offer a wide range of expertise in pathology and advanced laboratory diagnostics for precision testing. These laboratories include state-of-the-art testing services required for conducting in-depth biomarker analysis with a strong foundation of consultation for various CVDs.

The report offers insights for the below-mentioned end users:

• Hospitals and Diagnostic Laboratories (Largest and Fastest-Growing Category)
• Academic and Research Institutes
• Others